Cambridge Investment Research Advisors Inc. Sells 4,735 Shares of Haleon plc (NYSE:HLN)

Cambridge Investment Research Advisors Inc. reduced its holdings in shares of Haleon plc (NYSE:HLN – Get Rating) by 4.3% in the 4th quarter, HoldingsChannel.com reports. The fund owned 104,715 shares of the company’s stock after selling 4,735 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Haleon were worth $838,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Keystone Financial Group boosted its position in Haleon by 5.8% during the fourth quarter. Keystone Financial Group now owns 23,460 shares of the company’s stock worth $188,000 after purchasing an additional 1,278 shares during the period. Comerica Bank boosted its holdings in shares of Haleon by 1.8% during the 4th quarter. Comerica Bank now owns 109,289 shares of the company’s stock worth $891,000 after buying an additional 1,906 shares during the period. Kestra Private Wealth Services LLC grew its stake in Haleon by 27.1% in the 4th quarter. Kestra Private Wealth Services LLC now owns 12,797 shares of the company’s stock valued at $102,000 after buying an additional 2,730 shares during the last quarter. Lindbrook Capital LLC raised its holdings in Haleon by 76.1% in the 4th quarter. Lindbrook Capital LLC now owns 6,671 shares of the company’s stock valued at $53,000 after acquiring an additional 2,882 shares during the period. Finally, Tompkins Financial Corp acquired a new stake in Haleon during the fourth quarter worth approximately $31,000. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on HLN shares. Sanford C. Bernstein started coverage on Haleon in a research report on Tuesday, April 4th. They issued an “outperform” rating on the stock. Argus raised Haleon from a “hold” rating to a “buy” rating in a report on Thursday, April 6th. Investec began coverage on Haleon in a report on Thursday, February 23rd. They set a “sell” rating for the company. Finally, Barclays boosted their target price on shares of Haleon from GBX 360 ($4.51) to GBX 364 ($4.56) in a research report on Tuesday, January 31st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $364.00.

Haleon Price Performance

Shares of NYSE HLN opened at $8.65 on Monday. The business has a fifty day moving average price of $8.55 and a two-hundred day moving average price of $7.94. The company has a quick ratio of 0.62, a current ratio of 0.93 and a debt-to-equity ratio of 0.61. Haleon plc has a fifty-two week low of $5.59 and a fifty-two week high of $9.05.

Haleon Dividend Announcement

The business also recently declared a — dividend, which was paid on Thursday, April 27th. Investors of record on Friday, March 17th were paid a $0.0577 dividend. This represents a yield of 0.7%. The ex-dividend date of this dividend was Thursday, March 16th.

About Haleon

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.